Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026)

Denali Therapeutics has reported Operating Expenses over the past 9 years, most recently at $137.4 million for Q4 2025.

  • Quarterly Operating Expenses rose 5.79% to $137.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $555.3 million through Dec 2025, up 10.65% year-over-year, with the annual reading at $555.3 million for FY2025, 10.65% up from the prior year.
  • Operating Expenses was $137.4 million for Q4 2025 at Denali Therapeutics, roughly flat from $137.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $156.0 million in Q1 2023 and troughed at $79.1 million in Q1 2021.
  • The 5-year median for Operating Expenses is $119.9 million (2024), against an average of $118.9 million.
  • Year-over-year, Operating Expenses surged 43.55% in 2023 and then decreased 15.2% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $89.6 million in 2021, then rose by 29.0% to $115.6 million in 2022, then increased by 14.65% to $132.6 million in 2023, then fell by 2.06% to $129.8 million in 2024, then increased by 5.79% to $137.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Expenses are $137.4 million (Q4 2025), $137.4 million (Q3 2025), and $135.0 million (Q2 2025).